Global Antibiotics Market By Action Mechanism (Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, and Mycolic Acid Inhibitors), By Drug Class (Cephalosporin, Penicillin, Fluoroquinolone, Macrolides, Carbapenem, Aminoglycosides, Sulfonamides, and Others), By Region, Industry Analysis and Forecast, 2020 - 2026

The Global Antibiotics Market size is expected to reach $62.5 billion by 2026, rising at a market growth of 5.3% CAGR during the forecast period. Antibiotic is a substance that fights against bacterial and protozoan infections. Additionally, they help in treating many diseases like urinary tract infections, pneumonia, strep throat, skin infections, sinus infections, ear infections and many more. Antibiotics can be classified on various bases but the most common classification is done on the basis of spectrum of activity, chemical structures, and mode of action. Presently, the demand for beta-lactam and beta-lactamase inhibitors class of antibiotics is more among healthcare providers.

The antibiotics market is growing owing to the increasing consumption of antibiotics in middle and lower-income countries, huge investments in R&D activities by pharmaceutical companies, and the increasing number of infectious diseases. Although, the development of antibiotic resistance and the rising cost of drug approval hinder the growth of the antibiotic market. On the other hand, advanced prospect molecules and the development of novel combination therapies to cure antibiotic-resistant microbial infections are estimated to propel the market and provide great opportunities for the market players.

The increased cases of infectious diseases in developing regions like the Asia Pacific and the Middle East are estimated to support the market growth. According to the data provided by WHO, above 15% of the children’s death is caused by pneumonia. Similarly, tuberculosis is more prevalent in the South Asian and Sub-Saharan regions. Presently, the much-needed antibiotic treatment is accessible only to one-third of the infected population that further expands the disease burden.

By Action Mechanism

Based on Action Mechanism, the market is segmented into Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, and Mycolic Acid Inhibitors. RNA and Folic acid synthesis inhibitors are expected to witness notable CAGRs during the forecast period. The evolutions of various antiviral drugs that inhibit transcription and reverse transcription processes are expected to help in the growth of the market. Folic acid inhibitor sulfa drugs are estimated to expand as they have a broad range of applications.

By Drug Class

Based on Drug Class, the market is segmented into Cephalosporin, Penicillin, Fluoroquinolone, Macrolides, Carbapenem, Aminoglycosides, Sulfonamides, and Others. The other antibiotics category includes imidazoles, tetracyclines, monoclonal antibodies, and lincosamides. It is expected that the other antibiotic category will expand at a high CAGR over the forecast period. The innovation of monoclonal antibodies for people who have developed antibiotic-resistance is the main feature of this category.

Antibiotics Market Report Coverage

Report Attribute	Details
Market size value in 2019	USD 43.8 Billion
Market size forecast in 2026	USD 62.5 Billion
Base Year	2019
Historical Period	2016 to 2018
Forecast Period	2020 to 2026
Revenue Growth Rate	CAGR of 5.3% from 2020 to 2026
Number of Pages	221
Number of Tables	334
Report coverage	Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Companies Strategic Developments, Company Profiling, Competition Analysis
Segments covered	Action Mechanism, Drug Class, Region
Country scope	US, Canada, Mexico, Germany, UK, France, Russia, Spain, Italy, China, Japan, India, South Korea, Singapore, Malaysia, Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria
Growth Drivers	Increasing prevalence of infectious diseases Evolution of advanced products
Restraints	High cost associated in R&D

By Region

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. North America continues to attain a high market share in the antibiotic market worldwide. The Healthcare System in North America helps in the utilization of branded products, although, with the loss of exclusivity of certain molecules, sales of the region have declined significantly in the last few years. Latin America, specifically Brazil, with its notable growth in the pharmaceuticals industry is also expected to boost the growth of the market. The outbreak of some viruses like Ebola in Africa is anticipated to push the growth of the market in this region.

Free Valuable Insights: Global Antibiotics Market to reach a market size of $62.5 Billion by 2026

KBV Cardinal Matrix - Antibiotics Market Competition Analysis

The major strategies followed by the market participants are Acquisition and Partnerships. Based on the Analysis presented in the Cardinal matrix; Pfizer, Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., and Novartis AG are some of the forerunners in the Antibiotics Market. Companies such as Sanofi S.A., Bayer AG, etc. are some of the key innovators in Antibiotics Market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Johnson and Johnson, Merck & Co., Inc., Pfizer, Inc., Bayer AG, Novartis AG, Sanofi S.A., Abbott Laboratories, F. Hoffmann-La Roche Ltd., and Eli Lilly and Company.

Recent Strategies Deployed in Antibiotics Market

• Nov-2020: Merck & Co. introduced its novel antibiotic combination Recarbrio in the UK. The antibiotic cure infections caused by aerobic Gram-negative organisms in adults with finite treatment options.
• Oct-2020: Pfizer agreed to acquire Arixa, a private real estate lender. The acquisition will help Pfizer to advance the development program for Arixa’s leading asset, ARX-1796. The potential benefits of ARX-1796 provide patients and the healthcare system and potentially enable patients to leave the hospital earlier or avoid the requirement for the hospital admission.
• Aug-2020: Sanofi signed an agreement to acquire Principia Biopharma, a late-stage biopharmaceutical company. The acquisition will help Sanofi to expand its autoimmune disease drug line. It also helps in advancing their R&D transformation to boost the development of the most promising medicines that will address significant patient requirements.
• Jul-2020: Novartis together with its biosimilars division Sandoz signed an agreement with the Austrian Federal Government. The agreement aimed to strengthen the long-term future of integrated antibiotics manufacturing in Europe.
• Jun-2020: Roche came into partnership with SpeeDx Pty. Ltd., an Australian-based private company. The partnership is a significant inflection point for the company and enables more patients and clinicians around the world. It also allows access to the key diagnostic tools for the management of antibiotic resistance.
• Apr-2020: Sanofi entered into a collaboration with GSK, a British multinational pharmaceutical company. The collaboration aimed to develop an adjuvanted vaccine for COVID-19, using innovative technology from both companies. This technology produced an exact genetic match to proteins found on the surface of the virus. The DNA sequence encodes this antigen, combined into the DNA of the baculovirus expression platform, the basis of Sanofi’s licensed recombinant influenza product in the US.
• Mar-2020: La Roche entered into a collaboration with Forge Therapeutics, a biotechnology company. The collaboration aimed to license FG-LpxC LUNG, a novel antibiotic for curing serious lung infections attributed to antibiotic-resistant Gram-negative bacteria including Pseudomonas aeruginosa. The FG-LpxC LUNG program is developed to cure hospital-based infections, which include those cited on the CDC's most urgent threats list that commonly occurs in people with weakened immune systems and chronic lung diseases.
• Jan-2020: Sanofi took over Synthorx, a biotechnology company. This acquisition added on to its synthorin drugs for cancer and autoimmune indications to its pipeline. Synthorins are proteins that are altered by using a base pair technique to enhance their characteristics.
• Dec-2019: Johnson & Johnson is acquiring Bermekimab from XBiotech Inc. Bermekimab is an anti-IL-1alpha monoclonal antibody (mAb) in Phase 2 development for curing atopic dermatitis and hidradenitis suppurativa. The acquisition will help the company to improve its ability to assist patients, providing their decades-long heritage and intense expertise in immunology.
• Jul-2019: Merck & Co. announced the approval of Recarbrio by the FDA. Recarbrio is an injection antibiotic for adult patients with complicated urinary tract infections, or cUTIs, with limited or no treatment options. Along with that, it also cures adults with certain complicated intra-abdominal infections, or cIAIs, and which have limited or no treatment options.
• Oct-2018: Novartis entered into an agreement with Boston Pharmaceuticals, a biopharmaceutical company. The agreement aimed to develop three novel anti-infective drug candidates, adding to the Novartis Infectious Diseases portfolio. The portfolio has the potential to address the requirement for new agents to cure antibiotic resistant Gram-negative infections.
• Oct-2017: Roche partnered with Warp Drive Bio, a subsidiary of Revolution Medicines. The partnership focused on the development of new classes of antibiotics against multidrug-resistant bacterial infections. Together, they designed to advance multiple novel classes of natural antibiotics that show activity against clinically important, drug-resistant, Gram-negative pathogens by applying Warp Drive’s Genome Mining platform.
• Mar-2017: Pfizer introduced Zavicefta, a novel combination antibiotic. Zavicefta treats patients with certain confirmed or suspected Gram-negative bacterial infections who needed hospitalization, available in the U.K. and Germany. Zavicefta was developed in response to the urgent medical requirement for new antibiotics for difficult-to-treat Gram-negative bacteria.
• Jan-2017: Johnson & Johnson agreed to acquire Actelion Ltd, a pharmaceuticals and biotechnology company. The acquisition helped Actelion’s specialty in-market medicines and late-stage products compatible with Johnson & Johnson’s efforts to expand the attractive and complementary therapeutic areas and deliver patients with serious illnesses and significant unmet medical requirements.
• Aug-2016: Pfizer acquired AstraZeneca's development and commercialization rights to its late-stage small molecule anti-infectives business. The introduction of AstraZeneca’s complementary small molecule anti-infectives portfolio helped in expanding patient access to these important medicines. It also enhanced their global expertise and offerings in the important area of therapeutics. Additionally, they provide the opportunity for near-term revenue to grow.

Scope of the Study

Market Segments Covered in the Report:

By Action Mechanism

• Cell Wall Synthesis Inhibitors
• Protein Synthesis Inhibitors
• DNA Synthesis Inhibitors
• RNA Synthesis Inhibitors
• Mycolic Acid Inhibitors

By Drug Class

• Cephalosporin
• Penicillin
• Fluoroquinolone
• Macrolides
• Carbapenem
• Aminoglycosides
• Sulfonamides
• Others

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled

• GlaxoSmithKline PLC (GSK)
• Johnson and Johnson
• Merck & Co., Inc.
• Pfizer, Inc.
• Bayer AG
• Novartis AG
• Sanofi S.A.
• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Eli Lilly and Company

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Antibiotics Market, by Action Mechanism
1.4.2 Global Antibiotics Market, by Drug Class
1.4.3 Global Antibiotics Market, by Geography
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Approvals
3.2.4 Acquisition and Mergers
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2016-2020)
3.3.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, Oct – 2020, Jul) Leading Players

Chapter 4. Global Antibiotics Market by Action Mechanism
4.1 Global Cell Wall Synthesis Inhibitors Market by Region
4.2 Global Protein Synthesis Inhibitors Market by Region
4.3 Global DNA Synthesis Inhibitors Market by Region
4.4 Global RNA Synthesis Inhibitors Market by Region
4.5 Global Mycolic Acid Inhibitors Market by Region

Chapter 5. Global Antibiotics Market by Drug Class
5.1 Global Cephalosporin Market by Region
5.2 Global Penicillin Market by Region
5.3 Global Fluoroquinolone Market by Region
5.4 Global Macrolides Market by Region
5.5 Global Carbapenem Market by Region
5.6 Global Aminoglycosides Market by Region
5.7 Global Sulfonamides Market by Region
5.8 Global Others Market by Region

Chapter 6. Global Antibiotics Market by Region
6.1 North America Antibiotics Market
6.1.1 North America Antibiotics Market by Action Mechanism
6.1.1.1 North America Cell Wall Synthesis Inhibitors Market by Country
6.1.1.2 North America Protein Synthesis Inhibitors Market by Country
6.1.1.3 North America DNA Synthesis Inhibitors Market by Country
6.1.1.4 North America RNA Synthesis Inhibitors Market by Country
6.1.1.5 North America Mycolic Acid Inhibitors Market by Country
6.1.2 North America Antibiotics Market by Drug Class
6.1.2.1 North America Cephalosporin Market by Country
6.1.2.2 North America Penicillin Market by Country
6.1.2.3 North America Fluoroquinolone Market by Country
6.1.2.4 North America Macrolides Market by Country
6.1.2.5 North America Carbapenem Market by Country
6.1.2.6 North America Aminoglycosides Market by Country
6.1.2.7 North America Sulfonamides Market by Country
6.1.2.8 North America Others Market by Country
6.1.3 North America Antibiotics Market by Country
6.1.3.1 US Antibiotics Market
6.1.3.1.1 US Antibiotics Market by Action Mechanism
6.1.3.1.2 US Antibiotics Market by Drug Class
6.1.3.2 Canada Antibiotics Market
6.1.3.2.1 Canada Antibiotics Market by Action Mechanism
6.1.3.2.2 Canada Antibiotics Market by Drug Class
6.1.3.3 Mexico Antibiotics Market
6.1.3.3.1 Mexico Antibiotics Market by Action Mechanism
6.1.3.3.2 Mexico Antibiotics Market by Drug Class
6.1.3.4 Rest of North America Antibiotics Market
6.1.3.4.1 Rest of North America Antibiotics Market by Action Mechanism
6.1.3.4.2 Rest of North America Antibiotics Market by Drug Class
6.2 Europe Antibiotics Market
6.2.1 Europe Antibiotics Market by Action Mechanism
6.2.1.1 Europe Cell Wall Synthesis Inhibitors Market by Country
6.2.1.2 Europe Protein Synthesis Inhibitors Market by Country
6.2.1.3 Europe DNA Synthesis Inhibitors Market by Country
6.2.1.4 Europe RNA Synthesis Inhibitors Market by Country
6.2.1.5 Europe Others Market by Country
6.2.2 Europe Antibiotics Market by Drug Class
6.2.2.1 Europe Cephalosporin Market by Country
6.2.2.2 Europe Penicillin Market by Country
6.2.2.3 Europe Fluoroquinolone Market by Country
6.2.2.4 Europe Macrolides Market by Country
6.2.2.5 Europe Carbapenem Market by Country
6.2.2.6 Europe Aminoglycosides Market by Country
6.2.2.7 Europe Sulfonamides Market by Country
6.2.2.8 Europe Others Market by Country
6.2.3 Europe Antibiotics Market by Country
6.2.3.1 Germany Antibiotics Market
6.2.3.1.1 Germany Antibiotics Market by Action Mechanism
6.2.3.1.2 Germany Antibiotics Market by Drug Class
6.2.3.2 UK Antibiotics Market
6.2.3.2.1 UK Antibiotics Market by Action Mechanism
6.2.3.2.2 UK Antibiotics Market by Drug Class
6.2.3.3 France Antibiotics Market
6.2.3.3.1 France Antibiotics Market by Action Mechanism
6.2.3.3.2 France Antibiotics Market by Drug Class
6.2.3.4 Russia Antibiotics Market
6.2.3.4.1 Russia Antibiotics Market by Action Mechanism
6.2.3.4.2 Russia Antibiotics Market by Drug Class
6.2.3.5 Spain Antibiotics Market
6.2.3.5.1 Spain Antibiotics Market by Action Mechanism
6.2.3.5.2 Spain Antibiotics Market by Drug Class
6.2.3.6 Italy Antibiotics Market
6.2.3.6.1 Italy Antibiotics Market by Action Mechanism
6.2.3.6.2 Italy Antibiotics Market by Drug Class
6.2.3.7 Rest of Europe Antibiotics Market
6.2.3.7.1 Rest of Europe Antibiotics Market by Action Mechanism
6.2.3.7.2 Rest of Europe Antibiotics Market by Drug Class
6.3 Asia Pacific Antibiotics Market
6.3.1 Asia Pacific Antibiotics Market by Action Mechanism
6.3.1.1 Asia Pacific Cell Wall Synthesis Inhibitors Market by Country
6.3.1.2 Asia Pacific Protein Synthesis Inhibitors Market by Country
6.3.1.3 Asia Pacific DNA Synthesis Inhibitors Market by Country
6.3.1.4 Asia Pacific RNA Synthesis Inhibitors Market by Country
6.3.1.5 Asia Pacific Mycolic Acid Inhibitors Market by Country
6.3.2 Asia Pacific Antibiotics Market by Drug Class
6.3.2.1 Asia Pacific Cephalosporin Market by Country
6.3.2.2 Asia Pacific Penicillin Market by Country
6.3.2.3 Asia Pacific Fluoroquinolone Market by Country
6.3.2.4 Asia Pacific Macrolides Market by Country
6.3.2.5 Asia Pacific Carbapenem Market by Country
6.3.2.6 Asia Pacific Aminoglycosides Market by Country
6.3.2.7 Asia Pacific Sulfonamides Market by Country
6.3.2.8 Asia Pacific Others Market by Country
6.3.3 Asia Pacific Antibiotics Market by Country
6.3.3.1 China Antibiotics Market
6.3.3.1.1 China Antibiotics Market by Action Mechanism
6.3.3.1.2 China Antibiotics Market by Drug Class
6.3.3.2 Japan Antibiotics Market
6.3.3.2.1 Japan Antibiotics Market by Action Mechanism
6.3.3.2.2 Japan Antibiotics Market by Drug Class
6.3.3.3 India Antibiotics Market
6.3.3.3.1 India Antibiotics Market by Action Mechanism
6.3.3.3.2 India Antibiotics Market by Drug Class
6.3.3.4 South Korea Antibiotics Market
6.3.3.4.1 South Korea Antibiotics Market by Action Mechanism
6.3.3.4.2 South Korea Antibiotics Market by Drug Class
6.3.3.5 Singapore Antibiotics Market
6.3.3.5.1 Singapore Antibiotics Market by Action Mechanism
6.3.3.5.2 Singapore Antibiotics Market by Drug Class
6.3.3.6 Malaysia Antibiotics Market
6.3.3.6.1 Malaysia Antibiotics Market by Action Mechanism
6.3.3.6.2 Malaysia Antibiotics Market by Drug Class
6.3.3.7 Rest of Asia Pacific Antibiotics Market
6.3.3.7.1 Rest of Asia Pacific Antibiotics Market by Action Mechanism
6.3.3.7.2 Rest of Asia Pacific Antibiotics Market by Drug Class
6.4 LAMEA Antibiotics Market
6.4.1 LAMEA Antibiotics Market by Action Mechanism
6.4.1.1 LAMEA Cell Wall Synthesis Inhibitors Market by Country
6.4.1.2 LAMEA Protein Synthesis Inhibitors Market by Country
6.4.1.3 LAMEA DNA Synthesis Inhibitors Market by Country
6.4.1.4 LAMEA RNA Synthesis Inhibitors Market by Country
6.4.1.5 LAMEA Others Market by Country
6.4.2 LAMEA Antibiotics Market by Drug Class
6.4.2.1 LAMEA Cephalosporin Market by Country
6.4.2.2 LAMEA Penicillin Market by Country
6.4.2.3 LAMEA Fluoroquinolone Market by Country
6.4.2.4 LAMEA Macrolides Market by Country
6.4.2.5 LAMEA Carbapenem Market by Country
6.4.2.6 LAMEA Aminoglycosides Market by Country
6.4.2.7 LAMEA Sulfonamides Market by Country
6.4.2.8 LAMEA Others Market by Country
6.4.3 LAMEA Antibiotics Market by Country
6.4.3.1 Brazil Antibiotics Market
6.4.3.1.1 Brazil Antibiotics Market by Action Mechanism
6.4.3.1.2 Brazil Antibiotics Market by Drug Class
6.4.3.2 Argentina Antibiotics Market
6.4.3.2.1 Argentina Antibiotics Market by Action Mechanism
6.4.3.2.2 Argentina Antibiotics Market by Drug Class
6.4.3.3 UAE Antibiotics Market
6.4.3.3.1 UAE Antibiotics Market by Action Mechanism
6.4.3.3.2 UAE Antibiotics Market by Drug Class
6.4.3.4 Saudi Arabia Antibiotics Market
6.4.3.4.1 Saudi Arabia Antibiotics Market by Action Mechanism
6.4.3.4.2 Saudi Arabia Antibiotics Market by Drug Class
6.4.3.5 South Africa Antibiotics Market
6.4.3.5.1 South Africa Antibiotics Market by Action Mechanism
6.4.3.5.2 South Africa Antibiotics Market by Drug Class
6.4.3.6 Nigeria Antibiotics Market
6.4.3.6.1 Nigeria Antibiotics Market by Action Mechanism
6.4.3.6.2 Nigeria Antibiotics Market by Drug Class
6.4.3.7 Rest of LAMEA Antibiotics Market
6.4.3.7.1 Rest of LAMEA Antibiotics Market by Action Mechanism
6.4.3.7.2 Rest of LAMEA Antibiotics Market by Drug Class

Chapter 7. Company Profiles
7.1 GlaxoSmithKline PLC (GSK)
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.2 Johnson and Johnson
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental &Regional Analysis
7.2.4 Research & Development Expenses
7.2.5 Recent strategies and developments:
7.2.5.1 Acquisition and Mergers:
7.3 Merck & Co., Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expenses
7.3.1 Recent strategies and developments:
7.3.1.1 Product Launches and Product Expansions:
7.3.1.2 Approvals:
7.4 Pfizer, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Recent strategies and developments:
7.4.4.1 Acquisition and Mergers:
7.4.4.2 Product Launches and Product Expansions:
7.5 Bayer AG
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.6 Novartis AG
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Recent strategies and developments:
7.6.4.1 Partnerships, Collaborations, and Agreements:
7.7 Sanofi S.A.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Acquisition and Mergers:
7.7.5.2 Partnerships, Collaborations, and Agreements:
7.8 Abbott Laboratories
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 F. Hoffmann-La Roche Ltd.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.9.4 Research & Development Expense
7.9.5 Recent strategies and developments:
7.9.5.1 Partnerships, Collaborations, and Agreements:
7.10. Eli Lilly and Company
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Regional Analysis
7.10.4 Research & Development Expense

TABLE 1 Global Antibiotics Market, 2016 - 2019, USD Million
TABLE 2 Global Antibiotics Market, 2020 - 2026, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Antibiotics Market
TABLE 4 Product Launches And Product Expansions– Antibiotics Market
TABLE 5 Approvals– Antibiotics Market
TABLE 6 Acquisition and Mergers– Antibiotics Market
TABLE 7 Global Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 8 Global Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 9 Global Cell Wall Synthesis Inhibitors Market by Region, 2016 - 2019, USD Million
TABLE 10 Global Cell Wall Synthesis Inhibitors Market by Region, 2020 - 2026, USD Million
TABLE 11 Global Protein Synthesis Inhibitors Market by Region, 2016 - 2019, USD Million
TABLE 12 Global Protein Synthesis Inhibitors Market by Region, 2020 - 2026, USD Million
TABLE 13 Global DNA Synthesis Inhibitors Market by Region, 2016 - 2019, USD Million
TABLE 14 Global DNA Synthesis Inhibitors Market by Region, 2020 - 2026, USD Million
TABLE 15 Global RNA Synthesis Inhibitors Market by Region, 2016 - 2019, USD Million
TABLE 16 Global RNA Synthesis Inhibitors Market by Region, 2020 - 2026, USD Million
TABLE 17 Global Mycolic Acid Inhibitors Market by Region, 2016 - 2019, USD Million
TABLE 18 Global Mycolic Acid Inhibitors Market by Region, 2020 - 2026, USD Million
TABLE 19 Global Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 20 Global Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 21 Global Cephalosporin Market by Region, 2016 - 2019, USD Million
TABLE 22 Global Cephalosporin Market by Region, 2020 - 2026, USD Million
TABLE 23 Global Penicillin Market by Region, 2016 - 2019, USD Million
TABLE 24 Global Penicillin Market by Region, 2020 - 2026, USD Million
TABLE 25 Global Fluoroquinolone Market by Region, 2016 - 2019, USD Million
TABLE 26 Global Fluoroquinolone Market by Region, 2020 - 2026, USD Million
TABLE 27 Global Macrolides Market by Region, 2016 - 2019, USD Million
TABLE 28 Global Macrolides Market by Region, 2020 - 2026, USD Million
TABLE 29 Global Carbapenem Market by Region, 2016 - 2019, USD Million
TABLE 30 Global Carbapenem Market by Region, 2020 - 2026, USD Million
TABLE 31 Global Aminoglycosides Market by Region, 2016 - 2019, USD Million
TABLE 32 Global Aminoglycosides Market by Region, 2020 - 2026, USD Million
TABLE 33 Global Sulfonamides Market by Region, 2016 - 2019, USD Million
TABLE 34 Global Sulfonamides Market by Region, 2020 - 2026, USD Million
TABLE 35 Global Others Market by Region, 2016 - 2019, USD Million
TABLE 36 Global Others Market by Region, 2020 - 2026, USD Million
TABLE 37 Global Antibiotics Market by Region, 2016 - 2019, USD Million
TABLE 38 Global Antibiotics Market by Region, 2020 - 2026, USD Million
TABLE 39 North America Antibiotics Market, 2016 - 2019, USD Million
TABLE 40 North America Antibiotics Market, 2020 - 2026, USD Million
TABLE 41 North America Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 42 North America Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 43 North America Cell Wall Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
TABLE 44 North America Cell Wall Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
TABLE 45 North America Protein Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
TABLE 46 North America Protein Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
TABLE 47 North America DNA Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
TABLE 48 North America DNA Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
TABLE 49 North America RNA Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
TABLE 50 North America RNA Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
TABLE 51 North America Mycolic Acid Inhibitors Market by Country, 2016 - 2019, USD Million
TABLE 52 North America Mycolic Acid Inhibitors Market by Country, 2020 - 2026, USD Million
TABLE 53 North America Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 54 North America Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 55 North America Cephalosporin Market by Country, 2016 - 2019, USD Million
TABLE 56 North America Cephalosporin Market by Country, 2020 - 2026, USD Million
TABLE 57 North America Penicillin Market by Country, 2016 - 2019, USD Million
TABLE 58 North America Penicillin Market by Country, 2020 - 2026, USD Million
TABLE 59 North America Fluoroquinolone Market by Country, 2016 - 2019, USD Million
TABLE 60 North America Fluoroquinolone Market by Country, 2020 - 2026, USD Million
TABLE 61 North America Macrolides Market by Country, 2016 - 2019, USD Million
TABLE 62 North America Macrolides Market by Country, 2020 - 2026, USD Million
TABLE 63 North America Carbapenem Market by Country, 2016 - 2019, USD Million
TABLE 64 North America Carbapenem Market by Country, 2020 - 2026, USD Million
TABLE 65 North America Aminoglycosides Market by Country, 2016 - 2019, USD Million
TABLE 66 North America Aminoglycosides Market by Country, 2020 - 2026, USD Million
TABLE 67 North America Sulfonamides Market by Country, 2016 - 2019, USD Million
TABLE 68 North America Sulfonamides Market by Country, 2020 - 2026, USD Million
TABLE 69 North America Others Market by Country, 2016 - 2019, USD Million
TABLE 70 North America Others Market by Country, 2020 - 2026, USD Million
TABLE 71 North America Antibiotics Market by Country, 2016 - 2019, USD Million
TABLE 72 North America Antibiotics Market by Country, 2020 - 2026, USD Million
TABLE 73 US Antibiotics Market, 2016 - 2019, USD Million
TABLE 74 US Antibiotics Market, 2020 - 2026, USD Million
TABLE 75 US Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 76 US Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 77 US Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 78 US Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 79 Canada Antibiotics Market, 2016 - 2019, USD Million
TABLE 80 Canada Antibiotics Market, 2020 - 2026, USD Million
TABLE 81 Canada Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 82 Canada Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 83 Canada Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 84 Canada Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 85 Mexico Antibiotics Market, 2016 - 2019, USD Million
TABLE 86 Mexico Antibiotics Market, 2020 - 2026, USD Million
TABLE 87 Mexico Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 88 Mexico Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 89 Mexico Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 90 Mexico Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 91 Rest of North America Antibiotics Market, 2016 - 2019, USD Million
TABLE 92 Rest of North America Antibiotics Market, 2020 - 2026, USD Million
TABLE 93 Rest of North America Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 94 Rest of North America Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 95 Rest of North America Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 96 Rest of North America Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 97 Europe Antibiotics Market, 2016 - 2019, USD Million
TABLE 98 Europe Antibiotics Market, 2020 - 2026, USD Million
TABLE 99 Europe Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 100 Europe Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 101 Europe Cell Wall Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
TABLE 102 Europe Cell Wall Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
TABLE 103 Europe Protein Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
TABLE 104 Europe Protein Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
TABLE 105 Europe DNA Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
TABLE 106 Europe DNA Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
TABLE 107 Europe RNA Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
TABLE 108 Europe RNA Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
TABLE 109 Europe Others Market by Country, 2016 - 2019, USD Million
TABLE 110 Europe Others Market by Country, 2020 - 2026, USD Million
TABLE 111 Europe Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 112 Europe Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 113 Europe Cephalosporin Market by Country, 2016 - 2019, USD Million
TABLE 114 Europe Cephalosporin Market by Country, 2020 - 2026, USD Million
TABLE 115 Europe Penicillin Market by Country, 2016 - 2019, USD Million
TABLE 116 Europe Penicillin Market by Country, 2020 - 2026, USD Million
TABLE 117 Europe Fluoroquinolone Market by Country, 2016 - 2019, USD Million
TABLE 118 Europe Fluoroquinolone Market by Country, 2020 - 2026, USD Million
TABLE 119 Europe Macrolides Market by Country, 2016 - 2019, USD Million
TABLE 120 Europe Macrolides Market by Country, 2020 - 2026, USD Million
TABLE 121 Europe Carbapenem Market by Country, 2016 - 2019, USD Million
TABLE 122 Europe Carbapenem Market by Country, 2020 - 2026, USD Million
TABLE 123 Europe Aminoglycosides Market by Country, 2016 - 2019, USD Million
TABLE 124 Europe Aminoglycosides Market by Country, 2020 - 2026, USD Million
TABLE 125 Europe Sulfonamides Market by Country, 2016 - 2019, USD Million
TABLE 126 Europe Sulfonamides Market by Country, 2020 - 2026, USD Million
TABLE 127 Europe Others Market by Country, 2016 - 2019, USD Million
TABLE 128 Europe Others Market by Country, 2020 - 2026, USD Million
TABLE 129 Europe Antibiotics Market by Country, 2016 - 2019, USD Million
TABLE 130 Europe Antibiotics Market by Country, 2020 - 2026, USD Million
TABLE 131 Germany Antibiotics Market, 2016 - 2019, USD Million
TABLE 132 Germany Antibiotics Market, 2020 - 2026, USD Million
TABLE 133 Germany Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 134 Germany Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 135 Germany Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 136 Germany Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 137 UK Antibiotics Market, 2016 - 2019, USD Million
TABLE 138 UK Antibiotics Market, 2020 - 2026, USD Million
TABLE 139 UK Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 140 UK Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 141 UK Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 142 UK Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 143 France Antibiotics Market, 2016 - 2019, USD Million
TABLE 144 France Antibiotics Market, 2020 - 2026, USD Million
TABLE 145 France Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 146 France Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 147 France Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 148 France Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 149 Russia Antibiotics Market, 2016 - 2019, USD Million
TABLE 150 Russia Antibiotics Market, 2020 - 2026, USD Million
TABLE 151 Russia Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 152 Russia Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 153 Russia Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 154 Russia Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 155 Spain Antibiotics Market, 2016 - 2019, USD Million
TABLE 156 Spain Antibiotics Market, 2020 - 2026, USD Million
TABLE 157 Spain Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 158 Spain Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 159 Spain Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 160 Spain Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 161 Italy Antibiotics Market, 2016 - 2019, USD Million
TABLE 162 Italy Antibiotics Market, 2020 - 2026, USD Million
TABLE 163 Italy Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 164 Italy Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 165 Italy Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 166 Italy Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 167 Rest of Europe Antibiotics Market, 2016 - 2019, USD Million
TABLE 168 Rest of Europe Antibiotics Market, 2020 - 2026, USD Million
TABLE 169 Rest of Europe Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 170 Rest of Europe Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 171 Rest of Europe Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 172 Rest of Europe Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 173 Asia Pacific Antibiotics Market, 2016 - 2019, USD Million
TABLE 174 Asia Pacific Antibiotics Market, 2020 - 2026, USD Million
TABLE 175 Asia Pacific Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 176 Asia Pacific Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 177 Asia Pacific Cell Wall Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
TABLE 178 Asia Pacific Cell Wall Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
TABLE 179 Asia Pacific Protein Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
TABLE 180 Asia Pacific Protein Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
TABLE 181 Asia Pacific DNA Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
TABLE 182 Asia Pacific DNA Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
TABLE 183 Asia Pacific RNA Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
TABLE 184 Asia Pacific RNA Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
TABLE 185 Asia Pacific Mycolic Acid Inhibitors Market by Country, 2016 - 2019, USD Million
TABLE 186 Asia Pacific Mycolic Acid Inhibitors Market by Country, 2020 - 2026, USD Million
TABLE 187 Asia Pacific Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 188 Asia Pacific Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 189 Asia Pacific Cephalosporin Market by Country, 2016 - 2019, USD Million
TABLE 190 Asia Pacific Cephalosporin Market by Country, 2020 - 2026, USD Million
TABLE 191 Asia Pacific Penicillin Market by Country, 2016 - 2019, USD Million
TABLE 192 Asia Pacific Penicillin Market by Country, 2020 - 2026, USD Million
TABLE 193 Asia Pacific Fluoroquinolone Market by Country, 2016 - 2019, USD Million
TABLE 194 Asia Pacific Fluoroquinolone Market by Country, 2020 - 2026, USD Million
TABLE 195 Asia Pacific Macrolides Market by Country, 2016 - 2019, USD Million
TABLE 196 Asia Pacific Macrolides Market by Country, 2020 - 2026, USD Million
TABLE 197 Asia Pacific Carbapenem Market by Country, 2016 - 2019, USD Million
TABLE 198 Asia Pacific Carbapenem Market by Country, 2020 - 2026, USD Million
TABLE 199 Asia Pacific Aminoglycosides Market by Country, 2016 - 2019, USD Million
TABLE 200 Asia Pacific Aminoglycosides Market by Country, 2020 - 2026, USD Million
TABLE 201 Asia Pacific Sulfonamides Market by Country, 2016 - 2019, USD Million
TABLE 202 Asia Pacific Sulfonamides Market by Country, 2020 - 2026, USD Million
TABLE 203 Asia Pacific Others Market by Country, 2016 - 2019, USD Million
TABLE 204 Asia Pacific Others Market by Country, 2020 - 2026, USD Million
TABLE 205 Asia Pacific Antibiotics Market by Country, 2016 - 2019, USD Million
TABLE 206 Asia Pacific Antibiotics Market by Country, 2020 - 2026, USD Million
TABLE 207 China Antibiotics Market, 2016 - 2019, USD Million
TABLE 208 China Antibiotics Market, 2020 - 2026, USD Million
TABLE 209 China Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 210 China Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 211 China Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 212 China Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 213 Japan Antibiotics Market, 2016 - 2019, USD Million
TABLE 214 Japan Antibiotics Market, 2020 - 2026, USD Million
TABLE 215 Japan Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 216 Japan Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 217 Japan Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 218 Japan Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 219 India Antibiotics Market, 2016 - 2019, USD Million
TABLE 220 India Antibiotics Market, 2020 - 2026, USD Million
TABLE 221 India Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 222 India Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 223 India Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 224 India Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 225 South Korea Antibiotics Market, 2016 - 2019, USD Million
TABLE 226 South Korea Antibiotics Market, 2020 - 2026, USD Million
TABLE 227 South Korea Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 228 South Korea Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 229 South Korea Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 230 South Korea Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 231 Singapore Antibiotics Market, 2016 - 2019, USD Million
TABLE 232 Singapore Antibiotics Market, 2020 - 2026, USD Million
TABLE 233 Singapore Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 234 Singapore Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 235 Singapore Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 236 Singapore Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 237 Malaysia Antibiotics Market, 2016 - 2019, USD Million
TABLE 238 Malaysia Antibiotics Market, 2020 - 2026, USD Million
TABLE 239 Malaysia Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 240 Malaysia Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 241 Malaysia Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 242 Malaysia Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 243 Rest of Asia Pacific Antibiotics Market, 2016 - 2019, USD Million
TABLE 244 Rest of Asia Pacific Antibiotics Market, 2020 - 2026, USD Million
TABLE 245 Rest of Asia Pacific Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 246 Rest of Asia Pacific Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 247 Rest of Asia Pacific Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 248 Rest of Asia Pacific Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 249 LAMEA Antibiotics Market, 2016 - 2019, USD Million
TABLE 250 LAMEA Antibiotics Market, 2020 - 2026, USD Million
TABLE 251 LAMEA Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 252 LAMEA Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 253 LAMEA Cell Wall Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
TABLE 254 LAMEA Cell Wall Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
TABLE 255 LAMEA Protein Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
TABLE 256 LAMEA Protein Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
TABLE 257 LAMEA DNA Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
TABLE 258 LAMEA DNA Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
TABLE 259 LAMEA RNA Synthesis Inhibitors Market by Country, 2016 - 2019, USD Million
TABLE 260 LAMEA RNA Synthesis Inhibitors Market by Country, 2020 - 2026, USD Million
TABLE 261 LAMEA Others Market by Country, 2016 - 2019, USD Million
TABLE 262 LAMEA Others Market by Country, 2020 - 2026, USD Million
TABLE 263 LAMEA Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 264 LAMEA Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 265 LAMEA Cephalosporin Market by Country, 2016 - 2019, USD Million
TABLE 266 LAMEA Cephalosporin Market by Country, 2020 - 2026, USD Million
TABLE 267 LAMEA Penicillin Market by Country, 2016 - 2019, USD Million
TABLE 268 LAMEA Penicillin Market by Country, 2020 - 2026, USD Million
TABLE 269 LAMEA Fluoroquinolone Market by Country, 2016 - 2019, USD Million
TABLE 270 LAMEA Fluoroquinolone Market by Country, 2020 - 2026, USD Million
TABLE 271 LAMEA Macrolides Market by Country, 2016 - 2019, USD Million
TABLE 272 LAMEA Macrolides Market by Country, 2020 - 2026, USD Million
TABLE 273 LAMEA Carbapenem Market by Country, 2016 - 2019, USD Million
TABLE 274 LAMEA Carbapenem Market by Country, 2020 - 2026, USD Million
TABLE 275 LAMEA Aminoglycosides Market by Country, 2016 - 2019, USD Million
TABLE 276 LAMEA Aminoglycosides Market by Country, 2020 - 2026, USD Million
TABLE 277 LAMEA Sulfonamides Market by Country, 2016 - 2019, USD Million
TABLE 278 LAMEA Sulfonamides Market by Country, 2020 - 2026, USD Million
TABLE 279 LAMEA Others Market by Country, 2016 - 2019, USD Million
TABLE 280 LAMEA Others Market by Country, 2020 - 2026, USD Million
TABLE 281 LAMEA Antibiotics Market by Country, 2016 - 2019, USD Million
TABLE 282 LAMEA Antibiotics Market by Country, 2020 - 2026, USD Million
TABLE 283 Brazil Antibiotics Market, 2016 - 2019, USD Million
TABLE 284 Brazil Antibiotics Market, 2020 - 2026, USD Million
TABLE 285 Brazil Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 286 Brazil Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 287 Brazil Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 288 Brazil Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 289 Argentina Antibiotics Market, 2016 - 2019, USD Million
TABLE 290 Argentina Antibiotics Market, 2020 - 2026, USD Million
TABLE 291 Argentina Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 292 Argentina Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 293 Argentina Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 294 Argentina Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 295 UAE Antibiotics Market, 2016 - 2019, USD Million
TABLE 296 UAE Antibiotics Market, 2020 - 2026, USD Million
TABLE 297 UAE Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 298 UAE Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 299 UAE Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 300 UAE Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 301 Saudi Arabia Antibiotics Market, 2016 - 2019, USD Million
TABLE 302 Saudi Arabia Antibiotics Market, 2020 - 2026, USD Million
TABLE 303 Saudi Arabia Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 304 Saudi Arabia Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 305 Saudi Arabia Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 306 Saudi Arabia Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 307 South Africa Antibiotics Market, 2016 - 2019, USD Million
TABLE 308 South Africa Antibiotics Market, 2020 - 2026, USD Million
TABLE 309 South Africa Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 310 South Africa Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 311 South Africa Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 312 South Africa Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 313 Nigeria Antibiotics Market, 2016 - 2019, USD Million
TABLE 314 Nigeria Antibiotics Market, 2020 - 2026, USD Million
TABLE 315 Nigeria Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 316 Nigeria Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 317 Nigeria Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 318 Nigeria Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 319 Rest of LAMEA Antibiotics Market, 2016 - 2019, USD Million
TABLE 320 Rest of LAMEA Antibiotics Market, 2020 - 2026, USD Million
TABLE 321 Rest of LAMEA Antibiotics Market by Action Mechanism, 2016 - 2019, USD Million
TABLE 322 Rest of LAMEA Antibiotics Market by Action Mechanism, 2020 - 2026, USD Million
TABLE 323 Rest of LAMEA Antibiotics Market by Drug Class, 2016 - 2019, USD Million
TABLE 324 Rest of LAMEA Antibiotics Market by Drug Class, 2020 - 2026, USD Million
TABLE 325 Key Information – GlaxoSmithKline PLC (GSK)
TABLE 326 Key information –Johnson and Johnson
TABLE 327 key information - Merck & Co., Inc.
TABLE 328 Key Information – Pfizer, Inc.
TABLE 329 Key Information – Bayer AG
TABLE 330 Key Information – Novartis AG
TABLE 331 Key Information – Sanofi S.A.
TABLE 332 Key Information – Abbott Laboratories
TABLE 333 key information – F. Hoffmann-La Roche Ltd.
TABLE 334 Key Information – Eli Lilly and Company

List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2016-2020)
FIG 4 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2017, Oct – 2020, Jul) Leading Players
FIG 5 Recent strategies and developments: Merck & Co., Inc.
FIG 6 Recent strategies and developments: Pfizer, Inc.
FIG 7 Recent strategies and developments: Sanofi S.A.